Prescription medicine
Tedizolid Brand names: Sivextro
Tedizolid (Sivextro) is a prescription medicine with an FDA approval on record since 2014. No generic is listed; pharmacies paid $475.79 per Sivextro 200 mg tablet in the October 7, 2026 NADAC survey.
- No generic listed
Check it at the source: the tedizolid FDA label on DailyMed (effective February 27, 2026, Merck Sharp & Dohme LLC); the NDA 205435 record on Drugs@FDA; every tedizolid label on DailyMed.
Highlights of the record
FDA label of February 27, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageSIVEXTRO is an oxazolidinone antibacterial indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible microorganisms in adult and pediatric patients (at least 26 weeks gestational age and weighing at least 1 kg) ( 1.1 ) Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug-resistant bacteria and maintain the effectiven
Forms and strengths
- 200 mg
- 200 mg/4ml
Injection (powder) (lyophilized) for solution; film-coated tablet.
On the market
- Earliest approval on file
- June 20, 2014 Sivextro, Cubist Pharms Llc; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- December 31, 2030 Sivextro tablets; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $475.79 per tablet Sivextro 200 mg tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 785 through July 30, 2026
What is tedizolid used for?
From the label: indications and usageSIVEXTRO is an oxazolidinone antibacterial indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible microorganisms in adult and pediatric patients (at least 26 weeks gestational age and weighing at least 1 kg) ( 1.1 ) Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug-resistant bacteria and maintain the effectiveness of SIVEXTRO and other antibacterial drugs, SIVEXTRO should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. 1.1 Acute Bacterial Skin and Skin Structure Infections SIVEXTRO ® is indicated for the treatment of acute […]
FDA pharmacologic class: Oxazolidinone Antibacterial.
Source: FDA drug label (SIVEXTRO), NDA205436 (Cubist Pharms Llc), as published by Merck Sharp & Dohme LLC, effective February 27, 2026 (SPL set 75672079-589f-451a-bdbf-eaebcfcc80a9), via openFDA; the full label on DailyMed
Is there a generic for tedizolid (Sivextro)?
No generic tedizolid is approved (Drugs@FDA, October 8, 2026).
The Orange Book lists 7 patents for Sivextro tablets: the compound patent runs to December 31, 2030. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2014 earliest approval on file
- 2030 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for tedizolid (Sivextro)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $475.79 per Sivextro 200 mg tablet, up 7% from $445.50 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Sivextro 200 mg tablet (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Sivextro 200 mg tablet | Brand | $475.79 per tablet | $14,273.71 | +7% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What does the tedizolid label say about other medicines?
The tedizolid label names 5 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Buspirone | warnings and precautions | Commonly used serotonergic agents include serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, buspirone, serotonin 5-HT1 receptor agonists (triptans), and opioids, including meperidine. |
| Meperidine | warnings and precautions | Commonly used serotonergic agents include serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, buspirone, serotonin 5-HT1 receptor agonists (triptans), and opioids, including meperidine. |
| Methotrexate | drug interactions | If possible, an interruption in the treatment of the co-administered BCRP substrate medicinal product should be considered during treatment with SIVEXTRO, especially for BCRP substrates with a narrow therapeutic index (e.g., methotrexate or topotecan). |
| Rosuvastatin | drug interactions | If coadministration cannot be avoided, monitor for adverse reactions related to the concomitantly administered BCRP substrates, including rosuvastatin [see Clinical Pharmacology (12.3) ]. |
| Topotecan | drug interactions | If possible, an interruption in the treatment of the co-administered BCRP substrate medicinal product should be considered during treatment with SIVEXTRO, especially for BCRP substrates with a narrow therapeutic index (e.g., methotrexate or topotecan). |
Source: FDA drug label (SIVEXTRO), NDA205436 (Cubist Pharms Llc), as published by Merck Sharp & Dohme LLC, effective February 27, 2026 (SPL set 75672079-589f-451a-bdbf-eaebcfcc80a9), via openFDA; the full label on DailyMed
What do FAERS reports show for tedizolid?
The FDA Adverse Event Reporting System holds 785 reports that list tedizolid among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 51 are coded as a death and 239 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other oxazolidinone antibacterials
- the pharmacologic class, with prices and generics
- Tedizolid side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other